

Estetrol Therapy in Sjögren's Syndrome: An Open Proof of Concept

Gepubliceerd: 06-11-2008 Laatste bijgewerkt: 07-12-2022

N/A

Ethische beoordeling	Positief advies
Status	Werving gestopt
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON22190

Bron

Nationaal Trial Register

Verkorte titel

N/A

Aandoening

Primary Sjögren's syndrome

Ondersteuning

Primaire sponsor: EMC

Investigator-initiated study

Overige ondersteuning: Pantarhei Bioscience (sponsoring study medication, pharmacy and review costs)

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Primary endpoint consists of a composite endpoint concerning meaningful improvement across 2 or 3 Sjögren's syndrome disease domains: oral, ocular and laboratory test

Toelichting onderzoek

Achtergrond van het onderzoek

Design:

An open, proof-of-concept, investigator initiated study

Subjects:

Female postmenopausal patients with primary Sjögren's syndrome and complaints; no contraindications for estrogens especially no increased risk and/or history of thrombo-embolic events

Study Medication:

Estetrol, dose of 20 mg per day during 28 days.

Treatment regimen:

first 4 weeks run-in period with placebo, thereafter 4 weeks treatment with estetrol, followed by 14 days treatment with a progestogen.

Clinical phase:

Phase II (proof-of-concept)

Primary objective:

To explore overall response to treatment with estetrol in patients with primary Sjögren's syndrome.

Secondary objectives:

To assess:

- improvement in quantitative levels of SSA and/or SSB
- decrease in pilocarpine use during treatment.
- improvement in results of the SF36
- safety of estetrol treatment.

Primary Endpoints:

Primary endpoint consists of a composite endpoint concerning meaningful improvement across 2 of 3 Sjögren's syndrome disease domains: oral, ocular, and laboratory tests.

- Oral improvement will be defined as $\geq 20\%$ in the patient's assessment of dry eyes (on a 100 mm VAS) or $\geq 20\%$ improvement in total unstimulated salivary flow.
- Ocular improvement will be defined as $\geq 20\%$ improvement in either the patient's assessment of dry eyes by VAS or the results of the Schirmer's test without anaesthetic.
- Laboratory improvement will be defined as $\geq 20\%$ improvement in the serum IgG or the ESR.

Doel van het onderzoek

N/A

Onderzoeksopzet

November/December - recruitment

First patient in: November 2008

Last patient out: March 2009

Onderzoeksproduct en/of interventie

20 mg estetrol per day during 28 days

Contactpersonen

Publiek

Erasmus Medical Center

S.A.M. Ennecker-Jans
's-Gravendijkwal 230
Rotterdam
The Netherlands

Wetenschappelijk

Erasmus Medical Center

S.A.M. Ennecker-Jans
's-Gravendijkwal 230
Rotterdam
The Netherlands

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Have the capacity to understand and willing to sign an informed consent form.
2. Fulfill American-European consensus criteria for primary Sjögren's syndrome.
3. Postmenopausal women ≥ 18 and ≤ 70 years of age at the time of screening.
4. Body mass index ≥ 18 and ≤ 32 kg/m².
5. Have complaints consistent with oral and ocular dryness.
6. The screening laboratory test results must meet the following criteria: SSA and/or SSB positive.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Have a history of alcohol or substance abuse within the preceding 6 months.
2. Have a history of malignancy.
3. Have a history of trombo-embolic events or a positive lupus anticoagulant.
4. Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.
5. Clinically significant abnormal results of routine hematology, serum biochemistry, urinalysis, in the opinion of the Investigator at screening, and/or known ECG abnormalities.
6. Known clinically significant abnormal mammogram (presence of any non-cystic mass) within one year before study start.
7. Known clinically significant abnormalities of the uterus and/or ovaries detected earlier by examination and/or ultrasound.
8. A cervical smear with clinically relevant abnormal cytology within one year before study.
9. Previous use of estrogen/progestogen.
10. Use of hormone containing implant at any time.
11. Contraindications for using steroids.
12. Any enzyme affecting drugs from 30 days prior to Day 1 (see Appendix I) and the use of griseofulvin, phenytoin, barbiturates, carbamazepine, rimfampicin, nelfinavir, ritonavir, ketonazole, primidone, oxcarbazepine, topiramate, felbamate, herbal remedies containing hypericum perforatum (St. John's wort).
13. Are unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access.
14. Use of any investigational drug within 3 months prior to screening or within 5 half-lives of the investigational agent, whichever is longer.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Anders
Toewijzing:	N.v.t. / één studie arm
Blinding:	Enkelblind
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestopt
(Verwachte) startdatum:	13-11-2008
Aantal proefpersonen:	10
Type:	Werkelijke startdatum

Ethische beoordeling

Positief advies	
Datum:	06-11-2008
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL680

Register

NTR-old

Ander register

ISRCTN

ID

NTR1525

: PR 3084

ISRCTN wordt niet meer aangevraagd

Resultaten

Samenvatting resultaten

N/A